Navigation Links
Arteriocyte Receives FDA Approval to Initiate Cellular Therapy Trial for Treatment of Thermal Burn Wounds in Wounded Warriors
Date:1/31/2013

CLEVELAND, Jan. 31, 2013 /PRNewswire/ -- Arteriocyte, a leading biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts announced today approval from the Food and Drug Administration (FDA) to initiate a Phase I clinical trial using its Magellan® System technology in the treatment of thermal burn wounds. The FDA Investigational Device Exemption (IDE-15140) allows Arteriocyte and its clinical partners to initiate evaluation of autologous platelet gel (APG) (using the Magellan® Autologous Platelet Separator technology) as an adjunctive therapy for autologous skin grafting in patients with thermal injuries. This treatment has been developed in partnership with the United States Telemedicine and Advanced Technology Research Center (TATRC), and the University of Utah Health Science Center and Intermountain Burn Center. Arteriocyte is initiating a series of investigations employing Arteriocyte's Magellan® Autologous Platelet Rich Plasma and Bone Marrow Derived Stem Cell Based Therapies for Burn Wounds as part of Arteriocyte's Cellular Therapies for Battlefield Wounds Program.

The Magellan® System is an FDA 510(k) cleared medical device for the rapid production of Platelet Rich Plasma from blood and bone marrow that can be applied to a surgical site as surgeons deem necessary for their clinical use requirements.  Magellan® MAR01a technology enables the rapid Operating Room based "closed system" concentration of aspirated bone marrow, yielding an injectable tissue rich in platelets, hematopoietic stem cells and mesenchymal stem cells in as little as fifteen minutes. The self-contained Magellan® Unit provides critical ease-of-use and operator-independent consistency necessary for deployment in military medical operations. Arteriocyte has partnered with the U.S Military to de
'/>"/>

SOURCE Arteriocyte
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. PAREXEL Chief Operating Officer Dr. Mark A. Goldberg Receives Special Recognition Award
2. Leica Biosystems Receives FDA Approval for the Fully Automated Bond Oracle™ HER2 IHC System on the Leica BOND-MAX
3. Nephros Receives 510(k) Clearance for Hemodiafiltration System
4. ProUroCare Medical Receives FDA Clearance for ProUroScan Elasticity Imaging System
5. BONESUPPORT Receives Red Herring 2012 Top 100 Europe Award
6. Diabecline Antibiotic Receives Edison Award for Best New Pharmaceutical Product
7. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
8. Alexza Receives Complete Response Letter for Adasuve™ NDA
9. Ventana Receives FDA Clearance for p53 (DO-7) Image Analysis and Digital Read Applications
10. Marshall Edwards Receives $4 Million Subscription From Novogen In Rights Offering
11. New Chronic Wound Treatment Device Receives Award from Veterans Healthcare Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... -- Australian biopharmaceutical company Specialised Therapeutics Australia (STA) is pleased ... combination with gemcitabine, will be reimbursed via the Pharmaceutical ... from 1 November. In ... most common cause of cancer mortality. Pancreatic cancer ... lowest 5-year survival of all common cancers at 5.2%. ...
(Date:10/31/2014)... -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP)( ... the development of oral drug delivery systems, announces ... to discuss the clinical results from its Phase ... oral insulin capsules, to treat type 1 diabetes ... Eastern time. Shareholders and other interested ...
(Date:10/31/2014)... -- Today, Analysts Review released its research ... Bristol-Myers Squibb Co. (NYSE: BMY ), UnitedHealth ... (NYSE: SNY ) and Actavis plc (NYSE: ... publication. To reserve complementary membership, limited openings are available ... Reports ,On October 23, 2014, Celgene Corporation (Celgene) reported ...
Breaking Medicine Technology:Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 2Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 3Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 4Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 5Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 6Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 7Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 8Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 2Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 3Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 4Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 5Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 6
... BOZEMAN, Mont., May 01, 2007 /PRNewswire/ -- ... with their influenza virus-like particles (VLPs),induced heterosubtypic ... data were presented by Dr. Joel Haynes, ... Tenth Annual Conference on,Vaccine Research sponsored by ...
... 3, 2007 - Insmed Inc.,(Nasdaq:INSM) today announced positive ... company's drug, IPLEX(TM), in,patients with myotonic muscular dystrophy ... conducted at,the University of Rochester School of Medicine ... doses of IPLEX up to 1,mg/kg/day in six ...
Cached Medicine Technology:LigoCyte Pharmaceuticals Presents Data Showing Heterosubtypic,Protection Against Influenza Challenge With Virus-Like Particle,Immunization 2Insmed Announces Promising Results From IPLEX Phase II Myotonic,Muscular Dystrophy Clinical Study 2Insmed Announces Promising Results From IPLEX Phase II Myotonic,Muscular Dystrophy Clinical Study 3Insmed Announces Promising Results From IPLEX Phase II Myotonic,Muscular Dystrophy Clinical Study 4
(Date:10/31/2014)... kind, Rice University researchers have mapped how information flows ... become metastatic. The research reveals a common pattern in ... and form new tumors. Researchers say the commonality may ... the genetic switches that cancer must flip to form ... two of the main players in cancer metastasis. , ...
(Date:10/31/2014)... Colorado (PRWEB) October 31, 2014 Daily Gossip ... method is actually described as the fastest fat loss program ... in less than a month. , There is no wonder ... loss eBook of all time. The new nutrition and workout ... nutrition and fitness expert. , According to the author ...
(Date:10/31/2014)... 2014 With all the preparations families ... feels they may overlook one critical area – the ... concentration, school performance and even behavior. Typical children’s vision ... identify progressive vision problems, and to address this challenge, ... new initiative: The Awesome Eyes Student Vision Program. ...
(Date:10/31/2014)... may make it hard for you to remember simple things, ... house keys, a small study suggests. Tests on 18 ... called spatial memory -- was impaired when sleep apnea disrupted ... sleep weren,t affected. REM sleep is the deepest level of ... the first time that sleep apnea, an increasingly common medical ...
(Date:10/31/2014)... four older Americans say that either they or a ... according to the latest issue of The Gerontological Society ... ( PP&AR ), which goes on to show that ... to honor patients, end-of-life health care wishes. , This ... and Options ," features 12 articles that present new ...
Breaking Medicine News(10 mins):Health News:Decoding the emergence of metastatic cancer stem cells 2Health News:Decoding the emergence of metastatic cancer stem cells 3Health News:Xtreme Fat Loss Diet Review Reveals How to Transform Your Body in 25 Days 2Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 2Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 3Health News:Sleep Apnea May Steal Some of Your Memory: Study 2Health News:Advance directives can benefit patients, families, and health care system 2
... The nation,s theater owners were asked today by the head of a major Hollywood studio to have healthier snacks at their concession stands in addition to their ... ... ... ...
... eight times more likely to die, study finds , MONDAY, March ... hip are five to eight times more likely to die in ... Belgian researchers has found. , And, while the death rate after ... the break, it never returns to the death rate seen in ...
... of Medicine (BUSM) believe teaching the subject of unhealthy ... training and can be done within existing teaching venues. ... Medical Education , represent a national model for addressing ... use can be serious and chronic and despite its ...
... March 15 The HIMSS Electronic Health ... on two major regulations that implement healthcare IT incentive ... 2009 (ARRA).  One comment addressed the Office of the ... (IFR) on EHR certification criteria and standards.  The other ...
... mouse study suggests , MONDAY, March 15 (HealthDay News) ... a major role in regulating blood pressure, but a ... could also be key, at least after menopause begins. ... to have female chromosomes (XX) and females to have ...
... Mouse study suggests treatment aimed at immune system could work ... cells may one day be a viable treatment for people ... published online in the March 15-19 early edition of the ... its idea from the field of organ transplantation, where multipotent ...
Cached Medicine News:Health News:Movie Theaters Asked to Offer Healthier Snacks at Concession Stands 2Health News:Movie Theaters Asked to Offer Healthier Snacks at Concession Stands 3Health News:Movie Theaters Asked to Offer Healthier Snacks at Concession Stands 4Health News:Movie Theaters Asked to Offer Healthier Snacks at Concession Stands 5Health News:Movie Theaters Asked to Offer Healthier Snacks at Concession Stands 6Health News:Risk of Death Persists After a Hip Fracture 2Health News:Risk of Death Persists After a Hip Fracture 3Health News:Researchers recommend curriculum on unhealthy substance use 2Health News:HIMSS Electronic Health Record Association Responds to Proposed Meaningful Use and Certification Rules 2Health News:HIMSS Electronic Health Record Association Responds to Proposed Meaningful Use and Certification Rules 3Health News:HIMSS Electronic Health Record Association Responds to Proposed Meaningful Use and Certification Rules 4Health News:HIMSS Electronic Health Record Association Responds to Proposed Meaningful Use and Certification Rules 5Health News:Women's Chromosomes May Affect Blood Pressure 2Health News:Stem Cells Might One Day Treat Severe Asthma 2
... the solid, tested XiIIIPlus platform, the ... an unprecedented level of on-demand printing ... as unique features such as XML ... automatic calibration, flexible inlay positioning, multiple ...
... Built on the solid, tested ... offers an unprecedented level of on-demand ... well as unique features such as ... systems, automatic calibration, flexible inlay positioning, ...
... is ideal for applications that ... labels, such as tracking printed ... and identifying small products. The ... ensures text, graphics and bar ...
... The 105SL is the ... S Series™, and its also ... and processing capacity with rugged ... on a proven platform, the ...
Medicine Products: